TWM636366U - oral tablet - Google Patents

Abstract

An oral tablet, which includes a tablet body and a film coating layer, the tablet body is an object formed by mixing a plurality of granules, and the plurality of granules include a plurality of Hovenia dulcis fruit extract particles, a plurality of artichoke extract Phellinus Phellinus extract particles, several schisandra extract particles, and several sesame extract particles, the film coating layer is coated on the outer surface of the tablet body, and the oral tablet is convenient to carry and easy to eat.

Description

oral tablet

The present invention relates to an oral tablet, in particular to an oral tablet which is convenient to carry and eat.

Modern people live a busy life and have an unbalanced diet, which can easily lead to insufficient nutrient intake, which in turn leads to health problems.

According to the existing research, the intake of specific nutrients can help reduce liver damage. However, it is not easy to take in multiple nutrients that can help reduce liver damage at the same time through a general diet. Edible products for the prevention of liver damage are an important topic.

The main purpose of the present invention is to provide an oral tablet with compound formula, convenient to carry and easy to eat.

The oral tablet provided by the present invention includes: a tablet body, the tablet body is an object formed by mixing a plurality of granules, the plurality of granules include a plurality of Hovenia dulcis fruit extract particles, a plurality of artichoke Extract particles, several Phellinus extract particles, several Schisandra extract particles, and several sesame extract particles; and a film coating layer, the film coating layer is coated on the outer surface of the tablet body.

The oral tablet of the present invention is convenient to carry and easy to eat, and the outer surface of the tablet body can be coated with a film coating layer to fix the tablet body, so that the tablet body is not easy to collapse, not easy to deteriorate, easy to store, and convenient to take.

10: Tablet body

101: Outer ring surface

102: Convex

11: Hovenia dulcis seed extract granules

12: Artichoke Extract Granules

13: Phellinus extract granules

14:Schisandra extract granules

15: Sesame extract granules

20: film coating layer

Fig. 1 is a three-dimensional appearance view of a preferred embodiment of the present invention.

Fig. 2 is a side view of a preferred embodiment of the present invention.

Fig. 3 is an end view sectional view of a preferred embodiment of the present invention.

Fig. 4 is a partially enlarged cross-sectional view of a preferred embodiment of the present invention.

Please refer to FIG. 1 to FIG. 4 , the oral tablet of the present invention includes a tablet body 10 and a film coating layer 20 .

The lozenge body 10 is an object formed by mixing a plurality of particles; the plurality of particles includes a plurality of Hovenia dulcis fruit extract (Kenponashi Extract) particles 11, a plurality of Artichoke Extract (Artichoke Extract) particles 12, a plurality of Phellinus Linteus Extract granules 13 , Schisandra Extract granules 14 , and Sesame Extract granules 15 .

The particle size of each Hovenia dulcis fruit extract particle 11 is less than or equal to 180 microns (μm); the particle size of each Phellinus japonica extract particle 13 is greater than or equal to 180 microns (μm); the particle size of each Schisandra fruit extract particle 14 is less than or equal to 180 microns (μm); The particle size of each sesame extract particle 15 is less than or equal to 250 microns (μm); Can utilize the sieve screen of 80 mesh numbers (mesh) to screen Hovenia dulcis fruit extract particle 11 and Schisandra fruit extract particle 14, and make screening The particle size of Hovenia dulcis fruit extract particles 11 and Schisandra fruit extract particles 14 is less than or equal to 180 microns (μm), the sesame extract particles 15 can be screened with a 60-mesh sieve, so that the screened sesame extract particles 15 are less than or equal to 250 (μm).

The film coating layer 20 is coated on the outer surface of the tablet body 10, and it is mainly used to fix the tablet body 10, so that the tablet body 10 is not easy to collapse, not easy to deteriorate, easy to store, and easy to take. The film coating layer 20 May be a dark red film coat.

The oral tablet is elongated and weighs about 768.7 milligrams (mg). The oral tablet has a length of 16 to 17 mm and a width of 7 to 8 mm. It has an elongated outer ring surface 101 and two convex surfaces 102 , the height of the outer ring surface 101 is 4 to 5 mm, the opposite ends of the outer ring surface 101 are circular arc surfaces, the two convex surfaces 102 are respectively formed on the top and bottom sides of the outer ring surface 101, and each The height of the convex surface 102 protruding from the outer ring surface 101 is 1 to 1.5 mm.

Animal experiments are carried out by using the method of carbon tetrachloride-induced chronic liver injury in rats to evaluate the liver-protecting and health-care efficacy of the new oral tablets.

In the experiment, 50 male rats were randomly divided into 5 groups; the experiment was divided into 1 control group and 4 CCl ₄ experimental groups. Rats in the control group were given carboxymethyl cellulose (CMC) once a day; 4 groups of CCl ₄ experimental groups were CCl ₄ +CMC group and CCl ₄ + oral ingot group 1, 2, 3, CCl ₄ + CMC group was given carboxymethylcellulose once a day, CCl ₄ + oral tablet group 1 was given oral tablet 1 times of dose (318mg/kg) once a day, CCl ₄ + oral tablet group 2 was given oral tablet once a day 2 times the dose (636mg/kg), CCl ₄ + oral tablet group 3 was given 5 times the dose of oral tablet (1590mg/kg) once a day; after one full week, the rats in the control group were given olive oil orally twice a week (0.2mL/100g body weight); The rats in the CCl ₄ experimental group were orally administered 20% CCl ₄ twice a week for 8 weeks to induce chronic hepatitis; the oral dosage of the rats was based on the metabolic conversion ratio between humans and rats 6.2 Calculations.

Finally, at the end of the eighth week, blood was collected from the abdominal aorta of the rats, and the rats were sacrificed, and liver and spleen samples were taken by laparotomy for testing.

The statistics obtained from the experiment are as follows:

1. At the 8th week of the experiment, the rat plasma AST value of _{CCl 4} +CMC group was 2340.5±346.6U/L; the rat plasma AST value of CCl ₄ +oral ingot group 1 was 1797.1±604.0U/L; + Oral ingot group 1 rat plasma AST activity was significantly lower than CCl ₄ +CMC group.

2. At the 8th week of the experiment, the plasma ALT value of the rats in the CCl ₄ +CMC group was 1959.1±388.4U/L; the rat plasma ALT value of the CCl ₄ +oral tablet _group 1 was 1348.6±707.9U/L; The plasma ALT activity of the rats in the oral ingot group 1 was significantly lower than that in the CCl ₄ +CMC group.

3. After the experiment, the rat plasma albumin (Albumin) concentration of CCl ₄ +CMC group was 2.62 ± 0.41 (g/dL); the rat plasma albumin (Albumin) concentration of CCl ₄ + oral ingot group 1 was 3.04 ±0.26(g/dL), the concentration of rat plasma albumin (Albumin) in CCl ₄ + oral tablet group 1 was significantly higher than that in CCl ₄ +CMC group.

4. After the experiment, the absolute weight of the rat spleen of the CCl ₄ +CMC group was 1.98±0.54 grams (g), and the relative weight of the spleen was 0.46±0.14%; the absolute weight of the rat spleen of the CCl ₄ +oral ingot group 1 The weight was 1.32±0.37 grams (g), and the relative weight of the spleen was 0.31±0.11%; the absolute and relative weights of the spleens of the rats in the CCl ₄ + oral ingot group 1 were significantly lower than those in the CCl ₄ +CMC group.

5. After the experiment, the liver hydroxyproline (Hydroxyproline) concentration of CCl ₄ +CMC group was 1007.9±332.8 (μg/g tissue); the liver hydroxyproline (Hydroxyproline) concentration of CCl ₄ + oral ingot group 1 was 611.1±252.3 (μg/g tissue), the concentration of hydroxyproline (Hydroxyproline) in rat liver of CCl ₄ + oral ingot group 1 was significantly lower than that of CCl ₄ +CMC group.

6. After the experiment, the GSH concentration of the rats in the CCl ₄ +CMC group was 3.4±1.3 (μmol/g tissue); the GSH concentration of the rats in the CCl ₄ + oral ingot group 1 was 5.3±1.9 (μmol/g tissue); The GSH concentration of rats in CCl ₄ + oral ingot group 1 was significantly higher than that in CCl ₄ + CMC group.

7. After the experiment, the tissue fibrosis can be seen by Sirus Red staining. The degree of liver tissue fibrosis of the rats in CCl ₄ + oral tablet group 1, 2, and 3 was significantly lower than that in the CCl ₄ +CMC group.

As can be seen from the above-mentioned experimental results, the new oral tablet has effects such as reducing plasma ALT and AST values, increasing liver antioxidant GSH content, and reducing the degree of liver fibrosis to rat liver damage induced by carbon tetrachloride. And then reach the health care function of protecting the liver.

The new oral tablet is convenient to carry and eat, and is coated on the outer surface of the tablet body 10 with a film coating layer 20 to fix the tablet body 10, so that the tablet body 10 is not easy to collapse, not easy to deteriorate, and easy to store. Easy to take.

10: Tablet body

11: Hovenia dulcis seed extract granules

12: Artichoke Extract Granules

13: Phellinus extract granules

14:Schisandra extract granules

15: Sesame extract granules

20: film coating layer

Claims (5)

An oral tablet comprising: A lozenge body, the lozenge body is an object formed by mixing a plurality of particles, the plurality of particles includes a plurality of Hovenia dulcis fruit extract particles, a plurality of artichoke extract particles, a plurality of Phellinus extract particles, a plurality of schisandra extract particles, and a plurality of sesame extract particles; and A film coating layer, the film coating layer is coated on the outer surface of the tablet body. Oral tablets as described in claim 1, wherein The particle size of each Hovenia dulcis fruit extract particle is less than or equal to 180 microns; The particle size of each Phellinus Phellinus extract particle is greater than or equal to 180 microns; The particle size of each Schisandra extract particle is less than or equal to 180 microns; and The particle size of each sesame extract particle is less than or equal to 250 microns. The oral tablet as claimed in item 1, wherein the film coating layer is a dark red film coating layer. The oral tablet as described in any one of claims 1 to 3, wherein the oral tablet is elongated, has an outer ring surface and two convex surfaces, the opposite ends of the outer ring surface are arc surfaces, and the two convex surfaces are respectively formed on the top and bottom sides of the outer ring surface. The oral tablet as described in claim 4, wherein the oral tablet has a length of 16 to 17 mm and a width of 7 to 8 mm.

Images